Switching from Depakote to Lithium in Bipolar Disorder
Initiate lithium at a low dose while gradually tapering Depakote over 1-2 weeks, maintaining the Abilify 30 mg at bedtime unchanged throughout the transition, with close monitoring for mood destabilization.
Pre-Lithium Baseline Laboratory Assessment
Before starting lithium, obtain the following baseline tests 1:
- Complete blood cell count
- Thyroid function tests (TSH, free T4)
- Urinalysis
- Blood urea nitrogen (BUN) and creatinine
- Serum calcium
- Pregnancy test (if applicable)
Transition Strategy
Week 1: Cross-Titration Initiation
Start lithium while maintaining full Depakote dose:
- Begin lithium 300 mg twice daily (or 450 mg twice daily if clinically stable and not elderly) 1
- Continue Depakote 500 mg twice daily unchanged
- Continue Abilify 30 mg at bedtime unchanged 2
Rationale: The guideline recommends gradual tapering of prophylactic therapy to avoid precipitating relapse 1. Starting lithium before fully discontinuing Depakote provides mood stabilization coverage during the transition.
Week 2: Begin Depakote Taper
Reduce Depakote by approximately 25%:
- Decrease Depakote to 500 mg in morning, 250 mg at bedtime (or 250 mg twice daily)
- Continue titrating lithium upward based on serum levels and tolerability
- Target lithium level: 0.8-1.2 mEq/L 1
- Continue Abilify 30 mg at bedtime unchanged 2
Rationale: Guidelines recommend reducing concomitant mood stabilizers by approximately 25% every 2 weeks when converting to monotherapy 3. This gradual approach minimizes risk of mood destabilization 1.
Week 3-4: Complete Depakote Discontinuation
Continue stepwise Depakote reduction:
- Week 3: Reduce to 250 mg once daily
- Week 4: Discontinue Depakote completely
- Optimize lithium dosing to achieve therapeutic levels (0.8-1.2 mEq/L)
- Continue Abilify 30 mg at bedtime unchanged 2
Important Pharmacokinetic Considerations
No significant drug interactions exist between these medications:
- Aripiprazole does not affect lithium pharmacokinetics 4
- Lithium does not significantly alter aripiprazole levels (only 15-19% increase in exposure, not clinically significant) 5
- The combination of lithium and aripiprazole is safe and well-tolerated 4, 5
Monitoring During Transition
Clinical monitoring:
- Assess for early signs of mood episode relapse weekly 1
- Monitor for lithium toxicity symptoms (tremor, polyuria, polydipsia, confusion, nausea)
- Watch for withdrawal symptoms from Depakote (though uncommon with gradual taper)
Laboratory monitoring:
- Check lithium level 5-7 days after each dose adjustment
- Once stable lithium dose achieved, monitor lithium levels, renal function, and thyroid function every 3-6 months 1
Critical Pitfalls to Avoid
Do not abruptly discontinue Depakote: Abrupt discontinuation of mood stabilizers carries strong risk of precipitating status epilepticus (if treating seizures) or mood episode relapse 3. The guideline explicitly states that "antiepilepsy drugs should not be abruptly discontinued" and emphasizes gradual tapering while closely monitoring for relapse 1.
Maintain Abilify throughout: The aripiprazole should remain at 30 mg at bedtime unchanged during this transition 2. This provides additional mood stabilization and reduces relapse risk during the switch. Research demonstrates that combination therapy with lithium plus an atypical antipsychotic like aripiprazole is more effective than monotherapy in preventing relapse 1, 6.
Elderly patients require slower titration: If this patient is elderly, start lithium at lower doses (e.g., 150-300 mg daily) and titrate more slowly with careful monitoring for somnolence and dehydration 3.
Duration of Combination Therapy
Evidence suggests that the regimen needed to stabilize acute mania should be maintained for 12-24 months 1. After successful transition and 6-8 weeks of stability on lithium plus aripiprazole, consider whether to continue combination therapy or attempt monotherapy, recognizing that combination therapy (lithium plus valproate or lithium plus antipsychotic) is more effective than monotherapy in preventing relapse 1, 7.